| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIK3CB; DKFZp779K1237; MGC133043; PI3K; PI3KCB; PI3Kbeta; PIK3C1; p110-BETA;;PI3 kinase p110 beta |
| WB Predicted band size | Calculated MW: 123 kDa ; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human PI3 kinase p110 beta |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于PI3K p110β抗体的代表性文献(信息基于公开论文摘要整理)：
1. **文献名称**: "Selective role for the p110β phosphoinositide-3 kinase in signaling by the B-cell antigen receptor"
**作者**: Okkenhaug K, et al.
**摘要**: 该研究利用p110β特异性抗体，揭示其在B细胞抗原受体信号传导中的独特作用，发现p110β缺失会显著抑制B细胞增殖，而其他PI3K亚型无此效应。
2. **文献名称**: "The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ"
**作者**: Guillermet-Guibert J, et al.
**摘要**: 通过免疫沉淀和Western blotting(使用p110β抗体)，作者证明p110β介导GPCRs信号，并与p110γ在细胞迁移和肿瘤生长中功能互补。
3. **文献名称**: "Antitumor activity of a small-molecule inhibitor of the histone kinase PIK3CB"
**作者**: Jia S, et al.
**摘要**: 该研究采用p110β特异性抗体验证肿瘤模型中PIK3CB的蛋白表达水平，结合小分子抑制剂实验，证实靶向p110β可抑制多种癌症的进展。
4. **文献名称**: "Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis"
**作者**: Ciraolo E, et al.
**摘要**: 通过基因敲除模型和p110β抗体检测，发现p110β通过调控AKT/mTOR通路影响肿瘤代谢重编程，其缺失可抑制PTEN缺陷型肿瘤发展。
*注：实际文献引用时建议通过DOI或PMID核对原文信息。如需更近期研究，可补充具体年份或数据库检索关键词。*
The PI3K p110β antibody is a crucial tool for studying the class IA phosphatidylinositol 3-kinase (PI3K) isoform p110β, encoded by the *PIK3CB* gene. PI3Ks are lipid kinases regulating cell growth, survival, and metabolism. The p110β catalytic subunit forms heterodimers with regulatory subunits (e.g., p85) and is activated by receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), or oncogenic mutations. Unlike the closely related p110α isoform (frequently mutated in cancers), p110β is less commonly mutated but plays distinct roles in signaling, particularly in PTEN-deficient cancers, where it sustains PI3K pathway activity. It also exhibits unique lipid substrate preferences and interacts with RAS GTPases.
Antibodies targeting p110β enable detection of its expression, activation, and subcellular localization via techniques like Western blotting, immunohistochemistry (IHC), or immunoprecipitation (IP). These tools are vital in cancer research, as p110β drives tumor progression in contexts like prostate cancer, breast cancer, and PTEN-loss-driven malignancies. Additionally, p110β-specific inhibitors are under therapeutic exploration, making its selective detection critical for preclinical studies. Researchers also use these antibodies to dissect isoform-specific signaling mechanisms, particularly in GPCR-linked pathways or platelet activation. Validation of antibody specificity is essential due to structural homology among PI3K isoforms. Overall, p110β antibodies advance understanding of PI3K biology, disease mechanisms, and targeted therapy development.
×
